Skip to main content Accessibility help
×
Home

Essential fatty acids and mental health

Published online by Cambridge University Press:  02 January 2018

Brian Hallahan
Affiliation:
Royal College of Surgeons of Ireland and the Department of Psychiatry, Beaumont Hospital, Dublin, Ireland, UK
Malcolm R. Garland
Affiliation:
Royal College of Surgeons of Ireland and the Department of Psychiatry, Beaumont Hospital, Dublin, Ireland, UK
Corresponding
E-mail address:
Rights & Permissions[Opens in a new window]

Abstract

Image of the first page of this article
Type
Editorials
Copyright
Copyright © 2005 The Royal College of Psychiatrists 

The biological basis for the major psychiatric disorders is presumed to be a deficit or excess of neurotransmitters or abnormalities in their interactions with their respective receptors or transporters. Accordingly, the vast bulk of biological research, from genetics to psychopharmacology and from the study of signal transduction systems to in vivo molecular imaging, has placed the neurotransmitter and its target proteins centre-stage. This belies the fact that the dry weight of the mammalian brain is approximately 80% lipid (the highest of any organ) and also the steady accumulation of data demonstrating the crucial role of lipids, particularly long-chain polyunsaturated fatty acids (LC-PUFAs), in modulating neural function. The essential fatty acids (EFAs) are LC-PUFAs obtained exclusively through diet and they comprise 15–30% of the brain's dry weight. Their effect on neuronal membrane dynamics and therefore on receptor, transporter and neurotransmitter function is profound (see below). Moreover, the well-documented shift in the Western diet away from EFAs (and the omega-3 family in particular) parallels the large rise in all psychiatric disorders seen over the past century. Finally, along with the resurgence of interest in lipid–neuronal membrane interactions, there are now a considerable number of quality randomised controlled trials demonstrating the efficacy of EFAs in a diverse number of psychiatric conditions. (Additional references to those in the reference list are available from the corresponding author on request.)

FUNCTIONAL BIOCHEMISTRY OF THE ESSENTIAL FATTY ACIDS

The EFAs are divided into two groups, omega-3 (ω-3) and omega-6 (ω-6) fatty acids, depending on where the first double bond in the carbon chain occurs. The principal sources of EFAs are oily fish and certain vegetable oils. These are then processed into other long-chain polyunsaturated fatty acids (LC-PUFAs) by elongation and desaturation. The principal central nervous system-related EFAs are eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids (both ω-3) and arachidonic acid (ω-6). They are important components of phospholipids and cholesterol esters, which are themselves integral to the neuronal cell membrane, especially synaptic and dendritic membranes, but also intracellular membranes such as mitochondria and vesicles. If unavailable, they will be replaced by non-EFAs, changing the behaviour of the phospholipid molecules and affecting the tertiary and quaternary structures of membrane-bound receptors and associated neurotransmitters. The membrane phospholipid bilayer forms the matrix within which membrane proteins, such as receptors and ion channels, are embedded and to which membrane-associated proteins involved in second messenger systems are attached.

Additionally, cell signalling systems are regulated by lipid products, such as diacylglycerols, prostaglandins, leukotrienes, free fatty acids and hydroxy-fatty acids derived from phospholipid membranes. Moreover, EFAs are the precursors of the eicosanoids, a complex group of highly biologically active compounds encompassing the prostanoids (including prostaglandins, thromboxanes and prostacyclins) and leukotrienes. Eicosanoids derived from ω -3 EFAs have fewer inflammatory effects than those derived from ω -6 EFAs, underpinning the opposing effects that the ω-6 EFA families sometimes have (see below). Eicosanoids perform numerous regulatory functions in the brain and throughout the rest of the body, in particular for the regulation of immune and inflammatory responses.

There are now numerous animal studies relating to a wide variety of adverse effects associated with diets low in EFAs. As a converse example, De la Pressa Owens & Innis (Reference De la Pressa Owens and Innis1999) demonstrated that in pigs supplemented with EFAs from birth there was a doubling of the major monoamines in the frontal cortex.

MODERN DIET IS ASSOCIATED WITH DRAMATIC REDUCTIONS IN EFA INTAKE

The modern Western diet has evolved into a meat and saturated fat-rich diet, with falling consumption of fresh vegetables and fish. This has been coupled with a staggering rise in the consumption of seed oils (such as sunflower and soybean), whose polyunsaturated fatty acid content is predominantly ω-6, at the expense of ω-3, EFAs. The ω -6:ω-3 ratio is estimated to have been 0.4–2.8:1 in Palaeolithic and evolutionary diets (Reference Eaton, Eaton and SinclairEaton et al, 1998). These models did not even consider seafood consumption, which would bring the ratios even lower. The ω-6:ω-3 ratio is now estimated to have risen to 17:1 in our typical Western diet (Reference Eaton, Eaton and SinclairEaton et al, 1998). Moreover, wild and free-ranging animals have significantly more ω-3 fatty acids in their tissues than do currently produced commercial livestock. An overproduction of pro-thrombotic eicosanoids such as thromboxane, as well as pro-inflammatory leukotrienes and cytokines from a diet over-rich in ω -6 EFAs, has resulted and may be contributing to the rise in the incidence of such diseases as atheroma, thrombosis and a variety of inflammatory conditions (Reference Pischon, Hankinson and HotamisligilPischon et al, 2003). Such a sustained change in diet, as will now be discussed, may also be affecting mental health.

DIETARY REDUCTIONS IN EFA PARALLEL THE RISE IN PSYCHIATRIC DISORDER

Bearing in mind that fish are the principal source of ω-3 EFAs, Hibbeln (Reference Hibbeln1998) reports that the documented 60-fold variation across countries in the annual prevalence of major depression is strongly inversely correlated with national fish consumption. A similar inverse relationship exists for the prevalence of post-partum depression and fish consumption. In a survey of 3204 adults in Finland, infrequent fish consumption was associated with depressive symptoms in women (P<0.01) and a similar trend, although not statistically significant, was noted in men (Reference Tanskanen, Hibbeln and HintikkaTanskanen et al, 2001).

For bipolar affective disorder, Hibbeln's group have demonstrated that prevalence rates rise precipitously below an apparent annual fish intake threshold of approximately 75 lb per person, with prevalence rates of, for example, 0.04% in Taiwan (81.6 lb per person) and 6.5% in Germany (27.6 lb per person), which is a nearly 60-fold difference. The same group did not find a relationship between fish consumption and prevalence rates for schizophrenia.

For suicide, daily fish eating had a positive effect (odds ratio=0.81) in reducing the risk of death from suicide compared with subjects having a non-daily consumption in 17-year follow-up of 256 118 Japanese subjects (Reference HirayamaHirayama, 1990). With regard to dementia, in a study of elderly men, estimates of high ω-6 fatty acid intake were associated with cognitive impairment and, conversely, fish consumption was inversely associated with cognitive impairment, the significance in both cases persisting after controlling for confounders (Reference Kalmijn, Feskens and LaunerKalmijn et al, 1997).

LOWER EFA LEVELS IN PSYCHIATRIC ILLNESS

In one of several consistent studies on depression, Peet et al (Reference Peet, Murphy and Shay1998) demonstrated that total ω -3 fatty acid levels were decreased (5.39 mg/100 mg phospholipid compared with 9.04 mg/100 mg phospholipid for controls; P=0.02), DHA especially (1.61 mg/100 mg phospholipid compared with 2.50 mg/100 mg phospholipid; P=0.04), on red blood cell membranes in patients with major depressive disorder (n=15) compared with normal controls. The same group reported similar data in schizophrenia (Reference Peet, Laugharne and RangarajanPeet et al, 1995). We have demonstrated lowered plasma levels of cholesterol (Reference Garland, Hickey and CorvinGarland et al, 2000) and EFA (details available from the author upon request) in populations of patients with self-harm. There are now also considerable data supporting plasma EFA deficiency in attention-deficit hyperactivity disorder (e.g. Reference Richardson and PuriRichardson & Puri, 2000) and dementia (Reference Tully, Roche and DoyleTully et al, 2003).

SUPPLEMENTATION IN CLINICAL POPULATIONS: THE EVIDENCE

All but one of the four EFA supplementation randomised controlled trials (RCTs) in depression report significant improvement with supplementation. The largest of these studies (Reference Peet and HorrobinPeet & Horrobin, 2001) involved 70 patients, who remained on adequate standard therapy throughout the trial; at optimum dosage, there was a three-fold treatment-to-placebo effect, using a 50% reduction in Hamilton Rating Scale for Depression (HRSD) scores as evidence of clinical response. For bipolar affective disorder, in a 4-month RCT (Reference Stoll, Severus and FreemanStoll et al, 1999) of high-dose ω-3 fatty acids, patients (n=30) had longer periods of remission in the ω-3-treated group (P<0.02) and significant improvements in depressive, but not manic, symptomatology were observed, suggesting that depressive symptoms may be more responsive than manic symptoms to supplementation. For schizophrenia, the evidence is less equivocal. As reviewed recently (Reference Joy, Mumby-Croft and JoyJoy et al, 2003), only one of five small studies demonstrated substantial clinical improvement, and larger studies are clearly needed. There are only limited and inconsistent data on supplementation in attention-deficit hyperactivity disorder and dementia, although there are striking data on Huntington's chorea (n=17 patients) where treatment was associated not just with stabilisation but with reversal of clinical signs (Reference Vaddadi, Soosai and ChiuVaddadi et al, 2002).

There are various, generally positive data in psychopathic/aggressive/impulsive populations. In a carefully conducted RCT in young adult prisoners, a combination of ω-6 and ω-3 EFAs reduced offences by 26.3%, increasing to 35.1% if on supplementation for a minimum of 2 weeks (P<0.01; Reference Gesch, Hammond and HampsonGesch et al, 2002). The greatest reduction occurred for the most serious incidents including violence. As reviewed elsewhere (Reference Hallahan and GarlandHallahan & Garland, 2004), EFAs have proved beneficial also in stabilising aggression in a normal population of young university students at exam time (n=41) compared with randomised controls and in a population (n=30) of patients with borderline personality disorder treated for 8 weeks. Finally, we are shortly to conclude recruitment into an RCT of EFAs in a population of patients with self-harm.

CONCLUSIONS

There is no doubt that cerebral lipids, and EFA-derived LC-PUFAs in particular, have significant direct and indirect actions on cerebral function. Not only does the lipid composition of neural membranes affect the function of their embedded proteins, but also many LC-PUFAs are converted to neurally active substances. There is good evidence that psychiatric illness is associated with depletion of EFAs and, crucially, that supplementation can result in clinical amelioration. As well as challenging traditional views of aetiology and therapeutics in psychiatry, the clinical trial data may herald a simple, safe and effective adjunct to our standard treatments for many disabling conditions.

Footnotes

DECLARATION OF INTEREST

None.

References

De la Pressa Owens, S. & Innis, S. M. (1999) Docosahexanoic and arachidonic acid prevent a decrease in dopaminergic and serotonergic neurotransmitters in frontal cortex caused by a linoleic and alpha-linoleic acid deficient diet in formula-fed piglets. Journal of Nutrition, 129, 20882093.Google Scholar
Eaton, S. B., Eaton, S. B. 3rd, Sinclair, A., et al (1998) Dietary intake of long chain fatty acids during the palaeolithic. The return of omega-3 fatty acids to the food supply. I: Land-based animal products and their health effects. World Review of Nutrition and Dietetics, 83, 1223.CrossRefGoogle Scholar
Garland, M., Hickey, D., Corvin, A., et al (2000) Total serum cholesterol in relation to psychological parameters in parasuicide. British Journal of Psychiatry, 177, 7783.CrossRefGoogle ScholarPubMed
Gesch, C. B., Hammond, S. M., Hampson, S. E., et al (2002) Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. British Journal of Psychiatry, 181, 2228.CrossRefGoogle ScholarPubMed
Hallahan, B. & Garland, M. R. (2004) Essential fatty acids and their role in the treatment of impulsivity disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids, 71, 211216.CrossRefGoogle ScholarPubMed
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.CrossRefGoogle Scholar
Hibbeln, J. R. (1998) Fish consumption and major depression. Lancet, 351, 1213.CrossRefGoogle ScholarPubMed
Hirayama, T. (1990) Life Style and Mortality. A Large Census-Based Cohort Study in Japan. Basel: Karger.Google Scholar
Joy, C. B., Mumby-Croft, R. & Joy, L. A. (2003) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Systematic Reviews, 2, CD001257.Google Scholar
Kalmijn, S., Feskens, E. J., Launer, L. J., et al (1997) Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. American Journal of Epidemiology, 145, 3341.CrossRefGoogle ScholarPubMed
Peet, M. & Horrobin, D. F. (2001) A dose-ranging study of ethyl-eicosapentonate in treatment-unresponsive depression. Journal of Psychopharmacology, 15 (suppl.), A12.Google Scholar
Peet, M., Laugharne, J., Rangarajan, N., et al (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. Journal of Psychiatric Research, 29, 227232.CrossRefGoogle ScholarPubMed
Peet, M., Murphy, B., Shay, J., et al (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry, 43, 315319.CrossRefGoogle ScholarPubMed
Pischon, T., Hankinson, S., Hotamisligil, G. S., et al (2003) Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation, 108, 155160.CrossRefGoogle ScholarPubMed
Richardson, A. J. & Puri, B. K. (2000) The potential role of fatty acids in attention-deficit/hyper activity disorder. Prostaglandins, Leukotrienes and Essential Fatty Acids, 63, 7987.CrossRefGoogle Scholar
Stoll, A. L., Severus, E., Freeman, M. P., et al (1999) Omega-3 fatty acids in bipolar disorder. Archives of General Psychiatry, 56, 407412.CrossRefGoogle ScholarPubMed
Tanskanen, A., Hibbeln, J. R., Hintikka, J., et al (2001) Fish consumption and depression and suicidality in a general population. Archives of General Psychiatry, 58, 512513.CrossRefGoogle Scholar
Tully, A.M., Roche, H.M., Doyle, R., et al (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study. British Journal of Nutrition, 89, 483489.Google ScholarPubMed
Vaddadi, K. S., Soosai, E., Chiu, E., et al (2002) A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport, 13, 2933.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 291
Total number of PDF views: 430 *
View data table for this chart

* Views captured on Cambridge Core between 02nd January 2018 - 22nd January 2021. This data will be updated every 24 hours.

Access
Hostname: page-component-76cb886bbf-frjnl Total loading time: 0.755 Render date: 2021-01-22T05:31:12.409Z Query parameters: { "hasAccess": "1", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false }

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Essential fatty acids and mental health
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Essential fatty acids and mental health
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Essential fatty acids and mental health
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *